Esophageal Cancer Market

Market Overview:

The esophageal cancer market reached a value of USD 9.5 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 17.6 Billion by 2035, exhibiting a growth rate (CAGR) of 5.99% during 2025-2035.

The esophageal cancer market has been comprehensively analyzed in IMARC's new report titled "Esophageal Cancer Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Esophageal cancer refers to a type of cancer that develops in the cells of the esophagus, the muscular tube that carries liquid and food from the throat to the stomach. There are mainly two types of esophageal cancer: squamous cell carcinoma and adenocarcinoma. The former originates in the flat cells that line the esophagus, while the latter develops in the glandular cells that produce mucus in the lower portion of the esophagus. The most common symptom of the disorder is difficulty in swallowing, which can progress to a sensation of food being stuck in the throat. Other symptoms include pain or discomfort in the chest or back, unintentional weight loss, persistent coughing or hoarseness, heartburn or acid reflux, vomiting, regurgitation of food or liquid, chronic hiccups, etc. The diagnosis of esophageal cancer typically involves a combination of several tests and procedures. Various imaging tests, such as a barium swallow, CT scan, PET scan, etc., are used to visualize the esophagus and look for signs of cancerous cells. A biopsy, in which a small tissue sample is removed from the esophagus and examined under a microscope, is usually needed to confirm the diagnosis. Additionally, an endoscopy or laparoscopy may also be performed, depending on the location and size of the tumor, to help guide the biopsy or obtain additional tissue samples.

The increasing cases of chronic inflammation of the esophagus, which can result from gastroesophageal reflux disease (GERD), are primarily driving the esophageal cancer market. Furthermore, the rising prevalence of several associated risk factors, such as tobacco use, heavy alcohol consumption, obesity, certain medical conditions like achalasia, etc., is also propelling the market. In addition to this, the inflating utilization of endoscopic imaging techniques, including narrow-band imaging (NBI) and confocal laser endomicroscopy (CLE), for diagnosing esophageal cancer is creating a positive outlook for the market. These approaches use high-resolution images to detect abnormalities in the esophageal lining and can help in guiding biopsy sampling. Moreover, the widespread adoption of neoadjuvant therapy on account of its numerous benefits, such as the increased chance of complete tumor removal and decreased risk of disease recurrence, is further bolstering the market growth. Apart from this, the emerging popularity of multimodal approaches, which involve combining different treatment modalities, including chemotherapy, radiation therapy, surgery, etc., to improve outcomes for patients with esophageal cancer, is acting as another significant growth-inducing factor. Additionally, the rising adoption of immunotherapy, which involves using the body's immune system to fight cancer, for treating certain cases of esophageal cancer caused by specific genetic mutations, is also augmenting the market growth. Besides this, the escalating usage of minimally invasive surgeries, such as endoscopic resection, since they can reduce the risk of complications and speed up recovery time compared to traditional open procedures, is expected to drive the esophageal cancer market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the esophageal cancer market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for esophageal cancer and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the esophageal cancer market in any manner.

Drugs:

Keytruda (Pembrolizumab) is a humanized antibody, or programmed death-1 (PD-1) inhibitor, used in cancer immunotherapy to treat esophageal cancer. It is delivered via slow intravenous injection. Pembrolizumab inhibits lymphocytes' PD-1 receptors, blocking the ligands that would deactivate them and prevent an immunological response. This permits the immune system to identify and eliminate cancer cells, but it also prevents a vital process that keeps the immune system from attacking the body itself.

Opdivo (Nivolumab) is an anti-cancer drug employed in the treatment of esophageal cancer. Nivolumab's mechanism of action relies on its function as a monoclonal antibody that binds specifically to the PD-1 receptor on the surface of T cells, a type of white blood cell that is essential to the immune system's capacity to combat cancer. In normal circumstances, some cancer cells employ the PD-1 pathway to shield themselves from immune responses by inducing programmed death-ligand 1 (PD-L1), which interacts with the PD-1 receptor and prevents T-cell activation and growth. Nivolumab suppresses this interaction by binding to the PD-1 receptor, stopping tumor cells from evading immune recognition. This inhibition enhances T-cell reactivity, enhances the immune response against the tumor, and ultimately leads to the destruction of cancer cells.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the esophageal cancer market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the esophageal cancer market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current esophageal cancer marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the esophageal cancer market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the esophageal cancer market across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the esophageal cancer market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of incident cases (2019-2035) of esophageal cancer across the seven major markets?
• What is the number of incident cases (2019-2035) of esophageal cancer by age across the seven major markets?
• What is the number of incident cases (2019-2035) of esophageal cancer by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of esophageal cancer by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with esophageal cancer across the seven major markets?
• What is the size of the esophageal cancer patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of esophageal cancer?
• What will be the growth rate of patients across the seven major markets?
   

Esophageal Cancer: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for esophageal cancer drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the esophageal cancer market?
• What are the key regulatory events related to the esophageal cancer market?
• What is the structure of clinical trial landscape by status related to the esophageal cancer market?
• What is the structure of clinical trial landscape by phase related to the esophageal cancer market?
• What is the structure of clinical trial landscape by route of administration related to the esophageal cancer market?